related thrombocytosis: Does it increase the risk of thrombosis?
Sub-category: Health Services Research Category: Health Services Research Meeting: 2006 ASCO Annual Meeting Abstract No: 6091 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 6091 Author(s): S. Ahmed, R. K. Shahid, A. Sami, S. Yadav, I. Ahmad, D. Mirchandani, D. Popkin, K. Haider Abstract: Background: Gemcitabine is an antimetabolite agent that has demonstrated activity in various solid and hematological malignancies. Although thrombocytopenia is a known side effect, gemcitabine-related thrombocytosis has been uncommonly reported. Chemotherapy increases the risk of thrombo-embolism in patients with cancer. The study aimed to identify the incidence of gemcitabine-related thrombocytosis and to determine whether it has been associated with an increased risk of thrombo-embolism. Methods: Medical records of 175 consecutive adults patients with a malignant disease who received gemcitabine at Saskatoon Cancer Cent
Related Questions
- Will the fact that many of the Service Providers are overseas increase the risk that HMRC will look to employment businesses, as the parties with greater assets, to transfer debts?
- Do silicone breast implants increase the risk for breast cancer?
- related thrombocytosis: Does it increase the risk of thrombosis?
